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In areas of low tuberculosis (TB) prevalence, laboratory diagnosis of TB may essentially cover non-tuberculous mycobac-
teria (NTM) in addition to Mycobacterium tuberculosis (MTB). In this study, a semi-automated PCR workflow distin-
guishing MTB and NTM (AnyplexTM MTB/NTMe, Seegene) and subsequently detecting MTB isoniazid/rifampicin
resistance (AllplexTM MTB/MDRe, Seegene) was evaluated for replacing smear microscopy of acid-fast bacilli as the rapid
screening method for TB. With 279 clinical samples, 47 cultures positive for MTB and 76 for NTM, the AnyplexTM MTB/
NTMe assay and smear microscopy showed equal sensitivities (49.6% vs 50.8%, respectively) but AnyplexTM MTB/NTMe
was more sensitive for MTB (63.8% vs 25.6%) than for NTM (40.8% vs 64.5%). AllplexTM MTB/MDRe showed a slightly
higher sensitivity of 68.1% for MTB (32/47 positive, n = 222). Antibiotic resistance profiles were correctly identified for
all MTB isolates (one MDR isolate). Specificity was 100% for both assays. AnyplexTM MTB/NTMe detected all the 18
NTM species present in the study. The analytical performance of the evaluated high-throughput workflow was relatively
weak compared to culture but potentially adequate as a rapid screening method analogous to smear microscopy with addi-
tional differentiation between TB, MDR-TB, and NTM.
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The detection of Mycobacterium tuberculosis
(MTB), the causative agent of tuberculosis (TB), is
undeniably the number one priority when consider-
ing the laboratory diagnosis of mycobacteria. How-
ever, especially clinical settings of low TB-
prevalence, routine laboratory diagnosis may
include non-tuberculous mycobacteria (NTM) in
addition to MTB.
It is well known that the clinical significance of
isolating environmental NTM in clinical samples is
highly unknown compared to the obligatory
parasitic MTB (1). Indeed, clinical symptoms and
radiological findings are considered a prerequisite
for the diagnosis of NTM pulmonary disease
(NTMPD) (2) As NTMPD and TB may be
clinically indistinguishable but differ greatly in
antimicrobial therapy, a significant added value of
detecting NTM lies in the exclusion of TB (3,4).
Several cases of MDR-TB misdiagnosis due to
NTM infection have been described in areas where
NTM are not routinely analyzed (5,6). In countries
where they are routinely analyzed, NTM make up
a significant share of all mycobacterial laboratory
findings and rates are systematically increasing
(7,8).
Smear microscopy is still a widely used initial
screening method of TB (9). Although inexpensive,
the method does not identify different acid-fast
bacilli. Here, in a low TB-prevalence setting in Fin-
land, we evaluated the performance of two PCR
assays, AnyplexTM MTB/NTMe (Seegene, Seoul,
Korea) and AllplexTM MTB/MDRe (Seegene) using
the automated NIMBUS IVD nucleic acid extrac-
tion and PCR setup system (Hamilton Company,
Reno, NV, USA). The system was also surveyed as
a combined workflow of rapid TB screening
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analogous to smear microscopy but with additional
analysis of identification of TB, MDR-TB, and
NTM.
MATERIALS AND METHODS
Clinical material
A total of 279 clinical NALC-NaOH sedimented samples
(stored at 70 °C) and 35 culture-enriched (L€owenstein-
Jensen agar or BD BACTECTM MGITTM growth indicator
tubes (Becton, Dickinson and Company, Franklin Lakes,
NJ, USA)) mycobacterial isolates were collected for this
study during the year 2018 with 230 of pulmonary origin
(215 sputum or tracheal aspirate, 15 bronchoalveolar
lavage) and 49 of extrapulmonary origin (23 soft tissue, 15
urine, 10 pus, and 1 bone). The samples were collected,
and the study was performed retrospectively in the Clini-
cal Microbiology Laboratory of Fimlab Laboratories,
Tampere, Finland.
Data for smear microscopy (auramine staining) and
culture (L€owenstein-Jensen agar and BD BACTECTM
MGITTM growth indicator tubes) were available for all but
15 urine samples with culture results only. Additionally,
mycobacterial species identification (GenoType
Mycobacterium CM VER 2.0 assay, Hain Lifescience
GmbH, Nehren, Germany) and antimicrobial susceptibil-
ity results (determined by National Institute for Health
and Welfare, Finland) were available for cultured
mycobacterial isolates.
Sample pretreatment
To ensure safe working outside a biosafety cabinet, and to
reduce sample viscosity, a separate protocol inactivation
was employed, previously described by Qi et al. (10) for
the RealTime MTB assay (Abbott Molecular, Des Plaines,
IL, USA). Briefly, samples were mixed 1:3 with inactiva-
tion reagent (0.6% sodium hydroxide [wt/vol], 60% iso-
propanol [vol/vol], and 1.8% Tween 20 [vol/vol]) and
vortexed twice during a 1–24 h incubation at room tem-
perature. To assess whether the inactivation protocol had
any adverse effects to the workflow, a subset of samples
was analyzed without the inactivation pretreatment (non-
paired comparison to inactivated samples) and another
smaller subset with and without the inactivation pretreat-
ment (paired comparison). Samples for which no inactiva-
tion pretreatment was employed were known to be
negative for MTB.
DNA extraction, amplification, and result analysis
Two different PCR assays were used, AnyplexTM MTB/
NTMe (Seegene) and AllplexTM MTB/MDRe (Seegene).
DNA was extracted with NIMBUS IVD (Hamilton Com-
pany, Reno, NV, USA) system using the STARMag
96 9 4 Universal Cartridge Kit (Seegene) and amplified
with CFX96TM Real-Time PCR Detection System (Bio-
Rad Laboratories, Hercules, CA, USA). Extraction and
PCR setup were controlled with Seegene Launcher IVD
(Seegene) and result analysis with Seegene Viewer IVD
software (Seegene). All protocols were preset by the
assay manufacturer. DNA concentrations were measured
using NanoDropTM 2000 Spectrophotometer (Thermo-
Fisher Scientific, Waltham, MA, USA).
Workflow analysis
To assess the turnaround time of the workflow, including
AnyplexTM MTB/NTMe and subsequent testing of MTB-
positive samples with AllplexTM MTB/MDRe, durations of
different steps with realized sample batches were timed.
To assess the range of assay durations, the instrument
software was tested for analysis with a minimal and maxi-
mal number of samples, while still allowing for single
batch analysis.
Statistical analysis
Statistical tests were employed, when appropriate, using
the Prism software (GraphPad Software, San Diego, CA,
USA). Mann–Whitney U test and Wilcoxon signed-rank
test were used to compare non-paired and paired data of
DNA concentrations, respectively. Fisher’s exact test was
used for comparing sample clotting during DNA extrac-
tion and PCR results with different sample types. Sensitiv-
ity, specificity, and positive (PPV) and negative predictive
values (NPV) with 95% confidence intervals (CI) and
medians with interquartile range were used to describe
qualitative and quantitative results, respectively.
Ethics declaration
Leftover samples were analyzed retrospectively in this
study, and no patient data were collected. The study
design required no ethical committee approval. Informed
consent was not required for this study.
RESULTS
Clinical material
One hundred twenty-three of the 279 analyzed clini-
cal samples were culture-positive for mycobacteria,
47 with MTB (including 3 MDR and 2
M. africanum isolates) and 76 with NTM (consist-
ing of 9 different NTM species). With the culture-
enriched isolates included, a total of 18 NTM spe-
cies were analyzed in the study.
Performance of the AnyplexTM MTB/NTMe assay
A total of 279 clinical samples were analyzed with
the AnyplexTM MTB/NTMe assay. The assay
showed overall sensitivity of 49.6% (61/123) with
67.2% for smear-positive (SP) and 30.5% for
smear-negative (SN) samples. Separately, sensitivity
was 63.8% (30/47) for MTB detection (SP: 91.7%,
11/12; SN: 53.1%, 17/32) and 40.8% (31/76) for
NTM detection (SP: 61.2%, 30/49; SN: 3.7%, 1/27)
(Table 1 and 2). The overall sensitivity was equal
to that of smear microscopy (50.8%, 61/120) with
reciprocal figures for smear microscopy’s theoretical
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sensitivities for MTB (25.6%, 12/47) and NTM
(64.5%, 49/76) detection whatsoever. True assay
specificity and PPV were 100%, as the three
observed culture-negative, PCR-positive cases were
all recently culture-positive for MTB. NPV for
MTB/NTM, MTB, and NTM detection were
71.2%, 93.1% (229/246), and 81.9% (203/248),
respectively.
Of the nine NTM species present in clinical sam-
ples, M. avium, M. chelonae, and M. simiae were
detected by AnyplexTM MTB/NTMe (Table 3).
M. xenopi was the only NTM species not identified
in any smear-positive clinical sample. Examining
PCR data of culture-enriched isolates indeed
showed that the detection of M. xenopi was rela-
tively weak, showing late PCR cycles of 35.19 and
36.06 compared to the median of the whole culture-
enriched sample set (23.30, 21.62–26.21). All the 18
NTM species present in the study were detectable
in culture-enriched samples (Table 4).
Performance of the AllplexTM MTB/MDRe assay
Two hundred twenty-two of the available 279 clini-
cal samples were analyzed with the AllplexTM MTB/
MDRe assay. The AllplexTM MTB/MDRe assay
showed sensitivity of 68.1% (32/47) (SP: 91.7%, 11/
12; SN: 59.4%, 19/32) and NPV of 91.9% (171/
186) for MTB detection (Table 1 and 2). As with
AnyplexTM MTB/NTMe, true specificity and PPV
were 100%. 29/30 (96.7%) of the samples analyzed
as MTB-positive with AnyplexTM MTB/NTMe were
also analyzed as positive with AllplexTM MTB/
MDRe.
There were three MDR-MTB-positive samples
in the study, all culture-positive, smear-negative,
none detected by the AllplexTM MTB/MDRe
assay (MTB negative). However, both MTB and
MDR were detected from a culture-enriched
sample. No false-positive MDR results were
detected.
Table 1. Agreement of Anyplex MTB/NTMe and Allplex MTB/MDRe with mycobacterial culture and smear microscopy
results
Smear microscopy Anyplex MTB/NTMe Allplex MTB/
MDRe
AFB detection MTB detection NTM detection MTB/NTM
detection
MTB detection
Positive Negative Positive Negative Positive Negative Positive Negative Positive Negative
Culture (n = 279)
Positive 61 59 30 17 31 45 61 62 32 15
Negative 5 139 31 229 0 203 31 153 41 171
Smear microscopy2
Positive 11 1 30 19 41 20 11 1
Negative 17 15 1 26 18 41 19 13
AFB, acid-fast bacilli.
1All cases recently culture-positive for MTBC.
2All culture-positive.
Table 2. Performance data of AnyplexTM MTB/NTMe and AllplexTM MTB/MDRe assays
Method Sensitivity (CI), % Specificity (CI), % PPV (CI), % NPV (CI), %
Smear+ Smear Total
Smear microscopy
AFB
detection
50.8 (42.0–59.6) 96.5 (91.9–98.7) 92.4 (83.1–97.1) 70.2 (63.5–76.2)
Anyplex MTB/NTMe
MTB
detection
91.7 (62.5–100) 53.1 (36.5–69.1) 63.8 (49.5–76.1) 98.71 (96.1–99.7) 90.91 (75.7–97.6) 93.1 (89.2–95.7)
NTM
detection
61.2 (47.2–73.6) 3.7 (0–19.8) 40.8 (30.4–52.0) 100 (97.8–100) 100 (86.9–100) 81.9 (76.6–86.2)
MTB/
NTM
detection
67.2 (54.7–77.7) 30.5 (20.2–43.2) 49.6 (40.9–58.3) 98.11 (94.2–99.6) 95.31 (86.6–98.9) 71.2 (64.8–76.8)
Allplex MTB/MDRe
MTB
detection
91.7 (62.5–100) 59.4 (42.2–74.5) 68.1 (53.8–79.7) 97.71 (94.1–99.3) 88.91 (74.1–96.2) 91.9 (87.0–95.1)
AFB, acid-fast bacilli.
1True specificity and PPV were 100% as all culture-negative, PCR-positive cases had been recently culture-positive for
MTBC.
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Effect of the inactivation protocol in DNA extraction
and PCR results
The inactivation protocol had a significant effect
on DNA extraction yields (p = 0.003) when com-
pared between a subset of samples with the inac-
tivation protocol employed (11.8, 9.5–16 ng/µL;
n = 96) and a different subset of samples without
the inactivation protocol employed (13.9, 10–
32 ng/µL; n = 96) (non-paired subsets). The
observed difference was strengthened by a smal-
ler subset of samples analyzed both with and
without inactivation pretreatment (p = 0.0001)
(paired subset) (Fig. 1A). However, the analysis
of paired samples showed a mean 2.2-fold (1.6–
2.6, n = 14) shift in DNA concentration, whereas
the inactivation protocol diluted the sample four-
fold. A similar comparison of the same subset of
paired samples was done with the AnyplexTM
MTB/NTMe assay. Here, only a slight shift in
PCR cycle levels was seen with no significant dif-
ference (p = 0.14) (Fig. 1B). No PCR abortion
occurred in the study. However, sample clotting
events in the automated DNA extraction were
significantly more frequent with the inactivated
samples (13.6%, 25/184) compared to the non-in-
activated samples (3.2%, 3/95) (p = 0.006). This
increased the need for manual pipetting during
the DNA extraction protocol.
Table 3. Array of non-tuberculous mycobacteria present in the study: clinical samples
Species Smear+ Smear Total
Culture+ PCR+ % Culture+ PCR+ % Culture+ PCR+ %
M. avium 40 25 62.5 15 1 6.7 55 26 47.3
M. intracellulare 5 0 0 5 0 0
M. xenopi 3 0 0 1 0 0 4 0 0
M. chelonae 3 3 100 3 3 100
M. simiae 3 2 66.7 3 2 66.7
M. gordonae 2 0 0 2 0 0
M. szulgai 2 0 0 2 0 0
M. fortuitum 1 0 0 1 0 0
M. mucogenicum 1 0 0 1 0 0
Total 49 30 61.2 27 1 3.7 76 31 40.8
Table 4. Array of mycobacteria present in the study: culture-enriched isolates
Cultured isolates Anyplex MTB/NTMe Other species with positive
identification tested by manufacturerSpecies n MTB NTM
M. tuberculosis 2 2 M. bovis BCG
M. avium 3 3 M. asiaticum
M. abscessus 2 2 M. fallax
M. chelonae 2 2 M. massiliense
M. fortuitum 2 2 M. neoaurum
M. gordonae 2 2 M. paraseoulense
M. interjectum1 2 2 M. phlei
M. intracellulare 2 2 M. seoulense
M. kansasii 2 2 M. smegmatis
M. lentiflavum1 2 2 M. vaccae
M. szulgai 2 2
M. terrae 2 2
M. xenopi1 2 2
M. celatum1 1 1
M. malmoense1 1 1
M. marinum1 1 1
M. mucogenicum 1 1
M. simiae1 1 1
M. schimoidei1 1 1
NTM total 31 31
Other AFB 2 1
AFB, acid-fast bacilli (non-mycobacterial).
1Assay specificity not tested by manufacturer.
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Semi-automated workflow
The workflow of rapid TB screening with Any-
plexTM MTB/NTMe and subsequent testing of
MTB-positive samples with AllplexTM MTB/MDRe
is illustrated in Fig. 2. Assuming a 96-well plate
format, the workflow allowed analysis of 72 sam-
ples with 45 MTB-positive samples in one cycle.
The highest walkaway time was achieved with
batches of no more than 40 clinical samples (not to
mix with analysis of already extracted DNA). More
samples resulted in two separate interruptions of
the DNA extraction protocol, as the instrument
required more pipette tips and an empty waste bag.
Occasional sample clots further reduced walkaway
time and increased extraction time. There was a
separate interrupt in the extraction protocol for
manually transferring samples with clots. Without
these interruptions, the turnaround time of a 40-
sample batch was approximately 6 h from decon-
taminated samples to MTB/NTM (inactivation:
1.5 h, DNA extraction and PCR setup: 2.25 h,
amplification and result analysis: 2.25 h, and
hands-on time included). The turnaround time for
subsequent MDR-analysis of five MTB-positive
samples took approximately 3.5 h (PCR setup:
0.25 h, amplification: 3 h, result analysis, and
hands-on time: 0.25 h), making up a total turn-
around time of 9.5 h.
DISCUSSION
Rapid screening of TB is still widely based on
smear microscopy of acid-fast bacilli – a method
that could be replaced by more automated and
objective technology such as PCR. It is clear that a
PCR-based method is more expensive per test than
a nonspecific staining method. Additionally, a mul-
ti-stage PCR workflow such as the one evaluated in
this study requires a high level of infrastructure and
therefore does not suit small laboratories or low-in-
come settings. Compared to smear microscopy,
however, the system greatly increases the sensitivity
of rapid screening of TB as was shown in this
study. It also reduces the need for a high-expertise-
demanding method, and increases assay
Fig. 1. Effect of the inactivation protocol on sample quality and results on DNA extraction yield (A) and PCR cycles (B).
*Statistically significant difference.
Fig. 2. Illustration of the suggested semi-automated PCR
workflow. Vertical arrows show workflow to result with
live (dark) and dead (light) mycobacteria. Hands-on time
excluded.
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reproducibility with respect to workflow and result
interpretation. With MTB, smear microscopy has
the status as a determinant of TB infectivity,
although there are also studies where smear-nega-
tive cases have been a significant source of infection
(11,12). No similar practice has been described for
NTM (2). We previously showed that in this speci-
fic clinical setting of low TB-prevalence and low
population, an average of one sample was positive
for acid-fast bacilli per day (13). In such a clinical
setting, it would be easy to perform a subsequent
smear microscopy analysis for PCR-positive sam-
ples. Thus, the status as an infectivity determinant
does not essentially impair the applicability of PCR
screening.
The evaluated semi-automated system is not
exclusive for TB. The proposed TB screening work-
flow can be employed to complement a uniform
and comprehensive molecular diagnostic system.
This also allows the possibility of assigning auto-
mated work steps for other laboratory personnel
not working in a TB laboratory. Here, the evalu-
ated workflow also enabled a cost-efficient reflex
strategy of antibiotic resistance testing where MTB-
positive samples could be specifically selected for
subsequent antibiotic resistance analysis without
the need for overlapping analysis of all samples
(13). As a follow-up test for MTB-positive samples
with AnyplexTM MTB/NTMe assay, the AllplexTM
MTB/MDRe assay provided reliable results,
although more resistant MTB isolates would have
been needed to fully evaluate the assay’s MDR fea-
ture with 7 isoniazid and 18 rifampicin resistance
determining mutation targets.
Moreover, the evaluated semi-automated system
is not exclusive for TB. As Seegene holds an array
of different molecular diagnostic assays available
for its automated systems, the proposed TB screen-
ing workflow can be employed to complement a
uniform and comprehensive molecular diagnostic
system. This also allows the possibility of assigning
automated work steps for other laboratory person-
nel not working in a TB laboratory. Here, the eval-
uated workflow enabled a cost-efficient reflex
strategy of antibiotic resistance testing where MTB-
positive samples could be specifically selected for
subsequent antibiotic resistance analysis without
the need for overlapping analysis of all samples.
The system is analogous to the RealTime MTB sys-
tem employed by Abbott, but, as previously shown,
the Seegene TB assay selection may currently better
suit the needs of low TB-prevalence, low popula-
tion settings (13). The use of the Seegene Launcher
software allowed easy and fluent control of sam-
ples, as a single sample worklist could be used from
extraction to result analysis and follow-up testing
of selected samples. As a follow-up test for MTB-
positive samples with AnyplexTM MTB/NTMe
assay, the AllplexTM MTB/MDRe assay provided
reliable results, although more resistant MTB iso-
lates would have been needed to fully evaluate the
assay’s MDR feature with 7 isoniazid and 18 rifam-
picin resistance determining mutation targets.
Considering analytical performance, the two
evaluated PCR assays showed overall sensitivities
close to smear microscopy. While such figures are
far from definitive laboratory diagnosis and there-
fore do not compete with culture, the relatively low
sensitivity may be adequate for replacing smear
microscopy as the initial screening method. As
studies even for similar PCR assays have been
shown to have higher performance figures (14,15),
one must consider the possible adverse effects of
the inactivation protocol or sample storage on the
quality of the results. In addition, performance
evaluation studies of Seegene TB assays are gener-
ally performed using a manual extraction protocol,
and to our knowledge, there are no previous studies
assessing the performance of the NIMBUS IVD in
molecular diagnosis of TB. The inactivation proto-
col used in this study seemed, in fact, not to have
any apparent effect on assay results despite sample
dilution. However, as sample clotting occurred sig-
nificantly more often with inactivated samples, this
step seemed to be redundant in terms of reducing
sample viscosity. In terms of laboratory safety,
though, the process requires a separate MTB killing
step as a sample-handling instrument may not pre-
vent pathogen exposure if not situated inside a bio-
safety cabinet or a fume hood with an accessory
HEPA filter. This is exceptionally important when
handling MTB as laboratory transmission due to
prolonged exposure may be very difficult to identify
due to the slow nature of the MTB course of infec-
tion (16).
The AnyplexTM MTB/NTMe assay showed poor-
est performance on smear-negative NTM-positive
samples but also specifically on M. xenopi, even
with smear-positive samples. Depending on geo-
graphical location, M. xenopi is one of the species
most often reported to cause NTM pulmonary dis-
ease, in addition to M. abscessus, M. avium com-
plex, M. fortuitum, M. kansasii, and M. malmoense
(4). Even though the regional incidence of NTM
has a great diversity, M. xenopi is globally the third
most common NTM identified (8%) after the
M. avium complex (47%) and M. gordonae (11%)
(17-19). Closer inspection of the test insert revealed
that the manufacturer had in fact not tested speci-
ficity to M. xenopi. Other relevant species assayed
in this study, but not by the manufacturer, were
M. celatum, M. interjectum, M. lentiflavum,
© 2020 The Authors. APMIS published by John Wiley & Sons Ltd
on behalf of Scandinavian Societies for Medical Microbiology and Pathology 411
EVALUATION OF A TB-PCR WORKFLOW
M. malmoense, M. marinum, M. simiae, and
M. schimoidei. Except for M. marinum, which is the
causative agent of a superficial infection known as
fish tank granuloma, all of the mentioned NTM
species have been reported to cause pulmonary
disease (20). Within tuberculous mycobacteria, infor-
mation on specificity to M. africanum also appeared
to be lacking. Regionally important in West Africa,
testing assay specificity for M. africanum was highly
relevant even though different MTB complex species
have been recently proposed to comprise a single
species of MTB (21). Although only with individual
isolates, specificity of the AnyplexTM MTB/NTMe
assay for these eight NTM species and one MTB
variant was shown in this study with, as far as we
are aware, no previous demonstration elsewhere.
Most importantly, the AnyplexTM MTB/NTMe
assay showed reliable resolution between tubercu-
lous and non-tuberculous mycobacteria with no
observed false-positive results. This was based on
the relatively higher threshold for the generic
mycobacterial target (i.e., lower sensitivity for
NTM) than for the MTB-specific target, so that
MTB could not be falsely reported as NTM. How-
ever, this configuration did not compromise the
sensitivity of MTB detection, which was superior to
that of smear microscopy. The assays amplify the
known gene targets IS6110 and Mpb64 for MTB
detection, and a panmycobacterial 16S rRNA gene
target for NTM detection.
The AnyplexTM MTB/NTMe and AllplexTM
MTB/MDRe assays accompanied with the NIM-
BUS IVD system showed relatively low but ade-
quate overall sensitivity to be used as an initial
screening method for mycobacteria analogous to
smear microscopy. However, future research assess-
ing the cost efficiency of PCR compared to smear
microscopy is vital.
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